Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis.

Authors:
Dr Alfredo I Servín-Caamaño, Md
Dr Alfredo I Servín-Caamaño, Md
Hospital general de mexico
Dr
Adults medicine
Mexico city, Mexico | Mexico
Javier Cruz-Herrera
Javier Cruz-Herrera
Hospital General de México

Ann Hepatol 2014 May-Jun;13(3):343-52

Gastroenterology Department, Hospital General de México, México.

Background & Aim: Despite treatment with glucocorticoids, mortality remains high in patients with severe alcoholic hepatitis. Oxidative stress and depletion of mitochondrial glutathione are implicated factors in liver injury. The aim of this study was to evaluate the impact of the addition of metadoxine, a drug which possesses a multifactorial mechanism of action, including antioxidant properties, to standard treatment with glucocorticoids in patients with severe alcoholic hepatitis.

Material And Methods: This randomized open label clinical trial was performed in Mexico's General Hospital (Registry Key DIC/10/107/03/043). We randomized 70 patients with severe alcoholic hepatitis. The first group received prednisone (40 mg/day), and the second group received prednisone (40 mg/day) plus metadoxine tablets (500 mg three times daily). The duration of treatment in both groups was 30 days. Survival at 30 and 90 days, development of complications, adverse events and response to treatment (Lille model) were assessed.

Results: In the group receiving metadoxine, significant improvements were observed, as follows: survival at 30 days (74.3 vs. 45.7%, P = 0.02); survival at 90 days (68.6 vs. 20.0%, P = 0.0001). There was less development or progression of encephalopathy (28.6 vs. 60.0%, P = 0.008) and hepatorenal syndrome (31.4 vs. 54.3%, P = 0.05), and the response to treatment (Lille model) was higher in the metadoxine group (0.38 vs. 0.63, P = 0.001; 95% CI 0.11 to 0.40). There were no differences between groups regarding the development or progression of variceal hemorrhage or infection. The incidence of adverse events, mainly gastrointestinal, was similar in both groups.

Conclusions: Addition of metadoxine to glucocorticoid treatment improves the short-term survival of patients with severe alcoholic hepatitis and diminishes the development or progression of encephalopathy and hepatorenal syndrome.

Download full-text PDF

Source
January 2015
165 Reads
2.193 Impact Factor

Publication Analysis

Top Keywords

severe alcoholic
20
patients severe
20
alcoholic hepatitis
16
development progression
12
survival days
12
received prednisone
8
progression encephalopathy
8
lille model
8
adverse events
8
response treatment
8
hepatorenal syndrome
8
treatment glucocorticoids
8
treatment lille
8
prednisone mg/day
8
addition metadoxine
8
group received
8
treatment
7
metadoxine
5
patients
5
alcoholic
5

Similar Publications